Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Non Operating Income (2017 - 2025)

Cardiff Oncology (CRDF) has disclosed Non Operating Income for 11 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 0.77% to -$2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.8 million through Dec 2025, down 4441.03% year-over-year, with the annual reading at $5000.0 for FY2025, 112.82% up from the prior year.
  • Non Operating Income hit -$2.5 million in Q4 2025 for Cardiff Oncology, down from $716000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $922000.0 in Q1 2024 to a low of -$2.5 million in Q4 2025.
  • Historically, Non Operating Income has averaged $10368.4 across 5 years, with a median of $21000.0 in 2023.
  • Biggest YoY gain for Non Operating Income was 15240.0% in 2024; the steepest drop was 18930.77% in 2024.
  • Year by year, Non Operating Income stood at $84000.0 in 2021, then skyrocketed by 727.38% to $695000.0 in 2022, then tumbled by 101.87% to -$13000.0 in 2023, then plummeted by 18930.77% to -$2.5 million in 2024, then decreased by 0.77% to -$2.5 million in 2025.
  • Business Quant data shows Non Operating Income for CRDF at -$2.5 million in Q4 2025, $716000.0 in Q3 2025, and -$1000.0 in Q2 2025.